Investigating the role of ARID1a in pulmonary arterial hypertension
Official title: The Chromatin Remodeling Factor ARID1a and the Epigenetic Landscape In Pulmonary Arterial Hypertension
Funded at Icahn School of Medicine at Mount Sinai · NIH-11047747 · Data updated 2026-11-12
This study is looking at how a specific protein called ARID1a influences the development of pulmonary arterial hypertension (PAH), a serious lung condition, and how it interacts with another protein, EZH2, to help find new ways to treat this disease for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | March 5, 2024 |
| Project end | February 28, 2028 |
| Funding year | 2025 |
| Award (this year) | $755,295 |
| NIH project number | 5R01HL173203-02 |
| Project ID | NIH-11047747 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with pulmonary arterial hypertension.
✕Less likely to help
Patients with other forms of pulmonary hypertension or those without a confirmed diagnosis of PAH may not benefit from this research.
What this research studies
This research focuses on understanding how the chromatin remodeling factor ARID1a affects the development of pulmonary arterial hypertension (PAH), a serious and progressive lung disease. Researchers will explore the relationship between ARID1a and another protein, EZH2, to uncover how changes in gene expression contribute to the vascular remodeling seen in PAH. By studying these molecular interactions, the research aims to shed light on potential new therapeutic targets for this condition. Patients with PAH may benefit from insights gained into the underlying mechanisms of their disease.
Why it matters
Potential benefit: If successful, this research could lead to new treatment strategies for patients suffering from pulmonary arterial hypertension.
How similar studies have gone: While the role of ARID1a in PAH is not extensively studied, similar research in other conditions has shown promising results in understanding chromatin remodeling and its effects on disease.
Where this research is happening
-
Icahn School of Medicine at Mount Sinai
New York, United States Active
Researchers
- Principal investigator: Hadri, Lahouaria — Icahn School of Medicine at Mount Sinai
- Study coordinator: Hadri, Lahouaria
Related research
Other NIH-funded projects on the same topics.
-
Understanding how blood flow and pressure affect lungs in PAH
This grant studies how abnormal blood flow and pressure contribute to pulmonary arterial hypertension and how patient factors shape these effects, with the aim of guiding better therapies.
-
Asporin as a double-targeted therapy and biomarker for a serious artery disease
This project tests a protein called asporin as both a treatment and a biomarker for pulmonary arterial hypertension (PAH) to help people with this life-threatening condition.
-
Platelets and fibroblasts linked to energy use in a hard-to-treat blood vessel disease
A research team at the University of Pittsburgh is studying how platelet energy metabolism and fibroblast glutamine use interact in systemic sclerosis-related pulmonary arterial hypertension to improve diagnosis and treatment.
-
A biatrial dual‑lumen catheter to help the heart and lungs in pulmonary arterial hypertension
A new double‑lumen catheter is being developed to unload the right side of the heart and protect the lungs for people with pulmonary arterial hypertension.
-
Endothelial inflammation and Src kinase in early pulmonary arterial hypertension
Researchers are studying how inflammation in the lining of blood vessels and a protein called Src kinase contribute to early lung artery remodeling in people with mild PAH.
-
Cardiopulmonary chip model to study right heart disease from high blood pressure in the lungs
A tiny heart-lung chip is being developed to understand why the right side of the heart enlarges in people with pulmonary arterial hypertension and to test targeted treatments.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.